Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial

Back

ESC Professional Premium Access

Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial

Session: How to treat HFpEF in 2022 and beyond

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor K. Bunting (Birmingham, GB)

Event: ESC Congress 2022

Congress Presentation

About the speaker

Doctor Karina V Bunting

University of Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

0 follower

3 more presentations in this session

Treating HFpEF: State of the art 2022

Speaker: Professor S. Solomon (Boston, US)

Access

Slides

Video

Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled

Speaker: Professor J. Butler (Dallas, US)

Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

Speaker: Doctor J. Butt (Copenhagen, DK)

Access the full session

How to treat HFpEF in 2022 and beyond

Speakers: Doctor K. Bunting, Professor S. Solomon, Professor J. Butler, Doctor J. Butt

Access

Video

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial

About the speaker

Doctor Karina V Bunting

3 more presentations in this session

Treating HFpEF: State of the art 2022

Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled

Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

Access the full session

How to treat HFpEF in 2022 and beyond

About the event

ESC Congress 2022

ESC 365 is supported by